University Paul Sabatier of Toulouse
18
3
6
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
5.6%
1 terminated/withdrawn out of 18 trials
85.7%
-0.8% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Evaluation of the 2-year AVF Utilization Rate
Role: lead
Modified Left Atrial Maze Procedure for Concomitant AF Ablation
Role: lead
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
Role: collaborator
Evaluating a Health Literacy Intervention to Improve Colorectal Cancer Screening in Underserved Areas
Role: lead
Increasing Access to Fertility Preservation for Women with Breast Cancer
Role: lead
Guided Bone Regeneration in Alveolar Socket
Role: collaborator
Post-operative Quality of Life After AAA Management: EVAR Versus Open Repair
Role: lead
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
Role: collaborator
Pre-operative Screening of Functional Fragilities Before Open Aortic Surgery: a New Area
Role: lead
Type 1 Endoleak : Fenestrated Custom Made Endograft (FEVAR) Versus Open Surgery Explantation (OSR) : What's the Best
Role: lead
Rolled Pericardium Versus Cryopreserved Allograft to Treat Native or Prosthetic Aortic Infection
Role: lead
Outcomes After Visceral Aortic Coral Reef Surgery
Role: lead
Outcomes of Natives and Graft-related Femoral Reconstruction With Tubulized Pericardial Patchs
Role: lead
Molecular and Organizational Changes in the Human Oral Mucosa During Aging
Role: collaborator
Outcomes of Secondary Endovascular Aortic Repair After Initial Frozen Elephant Trunk Procedure
Role: lead
Usefulness of Doppler Ultrasound Carried Out by the Vascular Surgeon After Loco-regional Anesthesia for Preferred Access
Role: lead
Outcomes of FEVAR and BEVAR to Treat Secondary Type 1 Endoleak After EVAR: A Prospective Multicentre Study
Role: lead
Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids
Role: collaborator
All 18 trials loaded